Lamivudine treatment is associated with improved survival in fulminant hepatitis B

Liver International

Volumn 31, Issue 4, 2011, Pages 499-506

  Yu, Jian Wu ^a   Sun, Li Jie ^a   Yan, Bing Zhu ^a   Kang, Peng ^a   Zhao, Yong Hua ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Fulminant hepatitis B; Lamivudine; SIRS; Systemic inflammatory response syndrome

Indexed keywords

BILIRUBIN GLUCURONIDE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHYLPREDNISOLONE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG PULSE THERAPY; FEMALE; FULMINANT HEPATITIS B; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; MALE; MORTALITY; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; VIRUS LOAD;

BIOLOGICAL MARKERS; CHINA; COHORT STUDIES; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER FAILURE, ACUTE; MALE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79952479772     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02450.x     Document Type: Article

References (20)

1. Ostapowicz G, Fontana RJ, et al. US Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-54.
2. Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology 2008; 47: 1401-15.
3. Polson J, Lee WM. American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41: 1179-97.
4. Miyake Y, Sakaguchi K, Iwasaki Y, et al. New prognostic scoring model for liver transplantation in patients with non-acetaminophen-related fulminant hepatic failure. Transplantation 2005; 80: 930-6.
5. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439-55.
6. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993; 342: 273-5.
7. Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13: 256-63.
8. Yu JW, Sun LJ, Zhao YH, Kang P, Li SC. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci 2010; 55: 775-83.
9. Bernuaua J, Rueff B, Benhamou JP. Fulminant and sub-fulminant hepatic failure: definitions and causes. Semin Liver Dis 1986; 6: 97-106.
10. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74.
11. Roussos A, Koilakou S, Kalafatas I, et al. Lamivudine treatment for acute severe hepatitis B: report of a case and review of the literature. Acta Gastroenterol Belg 2008; 71: 30-2.
12. Roznovsky L, Orságová I, Kloudová A, et al. Lamivudine therapy in patients with fulminant hepatitis B. Klin Mikrobiol Infekc Lek 2007; 13: 59-65.
13. Wu Z, Han M, Chen T, Yan W, Ning Q. Acute liver failure: mechanisms of immune-mediated liver injury. Liver Int 2010; 30: 782-94.
14. Miyake Y, Iwasaki Y, Terada R, et al. Systemic inflammatory response syndrome strongly affects the prognosis of patients with fulminant hepatitis B. J Gastroenterol 2007; 42: 485-92.
15. Takahashi Y, Kumada H, Shimizu M, et al. A multicenter study on the prognosis of fulminant viral hepatitis: early prediction for liver transplantation. Hepatology 1994; 19: 1065-71.
16. Miyake Y, Iwasaki Y, Takaki A, et al. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med 2008; 47: 1293-9.
17. Dhiman RK, Seth AK, Jain S, Chawla YK, Dilawari JB. Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis. Dig Dis Sci 1998; 43: 1311-6.
18. Yu JW, Sun LJ, Zhao YH, et al. Prediction value of MELD scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment. J Gastroenterol Hepatol 2008; 23: 1242-9.
19. Sainokami S, Abe K, Sato A, et al. Initial load of hepatitis B virus (HBV), its changing profile, and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection. J Gastroenterol 2007; 42: 241-9.
20. Lisotti A, Azzaroli F, Buonfiglioli F, et al. Lamivudine treatment for severe acute HBV hepatitis. Int J Med Sci 2008; 5: 309-12.